New blood cancer drug clears first clinical trial
Advertisement
LONDON: A new blood cancer drug that targets a protein essential for growth of tumour cells has been found to be effective in patients resistant to current chemotherapies, a world first clinical trial has shown.
In the first-in-human study, researchers from UK looked at the efficacy of a new inhibitor, ONO/GS-4059, in the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma patients resistant to current chemotherapies. ONO/GS-4059 targets BTK, a protein essential for the survival and proliferation of tumour cells.
In the first-in-human study, researchers from UK looked at the efficacy of a new inhibitor, ONO/GS-4059, in the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma patients resistant to current chemotherapies. ONO/GS-4059 targets BTK, a protein essential for the survival and proliferation of tumour cells.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.